This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharma AG.
Reference
Costa-Scharplatz M, et al. Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden. Applied Health Economics and Health Policy : Sep 2015. Available from: URL: http://doi.org/10.1007/s40258-015-0193-2
Rights and permissions
About this article
Cite this article
Glycopyrronium in COPD: better outcomes, lower costs in Sweden. PharmacoEcon Outcomes News 736, 14 (2015). https://doi.org/10.1007/s40274-015-2424-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2424-z